These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 18188629)

  • 1. Full-field ERG and visual fields in patients 5 years after discontinuing vigabatrin therapy.
    Kjellström U; Lövestam-Adrian M; Andréasson S; Ponjavic V
    Doc Ophthalmol; 2008 Sep; 117(2):93-101. PubMed ID: 18188629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attenuation of the retinal nerve fibre layer and reduced retinal function assessed by optical coherence tomography and full-field electroretinography in patients exposed to vigabatrin medication.
    Kjellström U; Andréasson S; Ponjavic V
    Acta Ophthalmol; 2014 Mar; 92(2):149-57. PubMed ID: 23387307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication.
    Ponjavic V; Andréasson S
    Doc Ophthalmol; 2001 Jan; 102(1):63-72. PubMed ID: 11475366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vigabatrin and retinal changes.
    Jensen H; Sjö O; Uldall P; Gram L
    Doc Ophthalmol; 2002 Mar; 104(2):171-80. PubMed ID: 11999624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Visual field constriction and electrophysiological changes associated with vigabatrin.
    Besch D; Kurtenbach A; Apfelstedt-Sylla E; Sadowski B; Dennig D; Asenbauer C; Zrenner E; Schiefer U
    Doc Ophthalmol; 2002 Mar; 104(2):151-70. PubMed ID: 11999623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction.
    Harding GF; Wild JM; Robertson KA; Lawden MC; Betts TA; Barber C; Barnes PM
    Epilepsia; 2000 Nov; 41(11):1420-31. PubMed ID: 11077455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of vigabatrin on electrophysiology and visual fields in epileptics: a controlled study with a discussion of possible mechanisms.
    Comaish IF; Gorman C; Brimlow GM; Barber C; Orr GM; Galloway NR
    Doc Ophthalmol; 2002 Mar; 104(2):195-212. PubMed ID: 11999627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Visual field and electrophysiological abnormalities due to vigabatrin.
    van der Torren K; Graniewski-Wijnands HS; Polak BC
    Doc Ophthalmol; 2002 Mar; 104(2):181-8. PubMed ID: 11999625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visual function loss from vigabatrin: effect of stopping the drug.
    Johnson MA; Krauss GL; Miller NR; Medura M; Paul SR
    Neurology; 2000 Jul; 55(1):40-5. PubMed ID: 10891902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vigabatrin-associated visual field constriction in a longitudinal series. Reversibility suggested after drug withdrawal.
    Fledelius HC
    Acta Ophthalmol Scand; 2003 Feb; 81(1):41-6. PubMed ID: 12631018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in the ERG d-wave with vigabatrin treatment in a pediatric cohort.
    Dragas R; Westall C; Wright T
    Doc Ophthalmol; 2014 Oct; 129(2):97-104. PubMed ID: 25008578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is visual field constriction in epilepsy patients treated with vigabatrin reversible?
    Schmidt T; Rüther K; Jokiel B; Pfeiffer S; Tiel-Wilck K; Schmitz B
    J Neurol; 2002 Aug; 249(8):1066-71. PubMed ID: 12195456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal.
    Newman WD; Tocher K; Acheson JF
    Eye (Lond); 2002 Sep; 16(5):567-71. PubMed ID: 12194070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrophysiological evaluation of retinal function in children receiving vigabatrin medication.
    Kjellström U; Andréasson S; Ponjavic V
    J Pediatr Ophthalmol Strabismus; 2011; 48(6):357-65. PubMed ID: 21261244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Field-specific visual-evoked potentials: identifying field defects in vigabatrin-treated children.
    Harding GF; Spencer EL; Wild JM; Conway M; Bohn RL
    Neurology; 2002 Apr; 58(8):1261-5. PubMed ID: 11971096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examining visual field defects in the paediatric population exposed to vigabatrin.
    Spencer EL; Harding GF
    Doc Ophthalmol; 2003 Nov; 107(3):281-7. PubMed ID: 14711160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinal function abnormalities in patients treated with vigabatrin.
    Banin E; Shalev RS; Obolensky A; Neis R; Chowers I; Gross-Tsur V
    Arch Ophthalmol; 2003 Jun; 121(6):811-6. PubMed ID: 12796251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hand-held, dilation-free, electroretinography in children under 3 years of age treated with vigabatrin.
    Ji X; McFarlane M; Liu H; Dupuis A; Westall CA
    Doc Ophthalmol; 2019 Jun; 138(3):195-203. PubMed ID: 30826910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electroretinographic (ERG) responses in pediatric patients using vigabatrin.
    Moskowitz A; Hansen RM; Eklund SE; Fulton AB
    Doc Ophthalmol; 2012 Jun; 124(3):197-209. PubMed ID: 22426576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Symptomatic and asymptomatic visual loss in patients taking vigabatrin.
    Daneshvar H; Racette L; Coupland SG; Kertes PJ; Guberman A; Zackon D
    Ophthalmology; 1999 Sep; 106(9):1792-8. PubMed ID: 10485552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.